PRESS RELEASES
CARTICEPT MEDICAL™ RECEIVES 510(k) CLEARANCE FOR NAVIGATOR™
DELIVERY SYSTEM
(Alpharetta, GA, July 20, 2011)--Carticept Medical, Inc., a developer of
innovative products for the treatment of cartilage injuries and
osteoarthritis, today announced that it has received clearance from
the Food and Drug Administration to market its Navigator Delivery
System (Navigator DS) in the United States.
The Navigator DS is a computer-controlled, drug delivery system
designed to automate preparation and delivery of pain relieving
medications for joint pain. The system prepares
physician-prescribed injections from standard multi-dose anesthetic
and steroid drug vials. In addition to eliminating multiple needle
exposures to health care workers and minimizing the potential for
contamination of the medication, automating this procedure ensures
accurate dose preparation and saves significant labor for a busy
physician practice. The injection is then delivered into the
painful joint under precise computer control. The Navigator DS
automates accurate medical record keeping by recording the treatment
data for transfer to an electronic record management system or
direct print-out.
"The Navigator DS is the first injection system of its kind ,” said
Timothy J. Patrick, President and Chief Executive Officer of
Carticept. "Receiving FDA clearance is an important milestone for
Carticept Medical that will allow us to launch this proprietary
technology to the U.S. orthopedic and sports medicine market..”
“This technology can be a valuable tool for the accurate and
efficient delivery of injections,” said John Reach, MD, Director,
Yale Foot and Ankle Service, Department of Orthopaedic Surgery, Yale
University School of Medicine. “This system can significantly
enhance practice logistics and increase patient throughput in
orthopedic and sports medicine clinics.”
About Carticept Medical, Inc.
Based in Alpharetta, Ga., Carticept Medical, Inc. is a privately held medical device company established in 2005 to develop and market innovative solutions for patients with osteoarthritis or cartilage damage. Major investors include Domain Associates, New Enterprise Associates and SonoSite, Inc. Additional information is available on the company's web site at www.carticept.com.
Contact:
Barry Hassett
Vice President, Marketing
Carticept Medical, Inc.
770-754-3800
|
